Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

NOVEL THERAPY TO TREAT OTITIS MEDIA

Award Number: R43HD058400
ORGANIZATION: NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 06/01/2008
PERIOD OF PERFORMANCE END DATE: 05/31/2009

Group Awards By:

View Award Description

NOVEL THERAPY TO TREAT OTITIS MEDIA - DESCRIPTION (provided by applicant): Otitis media is a common childhood disease with annual direct costs estimated to exceed $3 billion. Otitis media is the most frequent cause of pediatric practitioner visits and results in more than 20 million antibiotic prescriptions annually. However, the pathogens associated with otitis media have become increasingly resistant to the prescribed antibiotics. Molecular examination of chronic cases of otitis media demonstrates the presence of bacteria encased in complex microbial communities known as biofilms. Antibiotic agents have proven to be ineffective against biofilm infections seen in chronic otitis media. A therapy that is effective against both chronic and acute otitis media, that does not induce microbial resistance, and that is effective against biofilms would be highly beneficial and have significant commercial potential. The goal of this project is to develop a unique, safe, and efficacious treatment for both acute and chronic otitis media. Prototype formulations will be tested in vitro and in an animal model of otitis media. The Specific Aims of the proposal are: Specific Aim 1. Formulate Iocide for use in treating otitis media Specific Aim 2. Evaluate Iocide for antibacterial activity on planktonic and biofilm bacteria in vitro Specific Aim 3. Demonstrate the effectiveness and safety of Iocide in an animal model of otitis media. PUBLIC HEALTH RELEVANCE: Otitis media is a common childhood disease with annual direct costs estimated to exceed $3 billion. Otitis media is the most frequent cause of pediatric practitioner visits and results in more than 20 million antibiotic prescriptions annually. Consequent to the widespread use of antibiotics, the pathogens associated otitis media have become increasingly resistant to antibiotic therapy. Public Health Relevance: This Public Health Relevance is not available.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2008 ( Subtotal = $107,000 )
2008	2008	BIOMEDICAL DEVELOPMENT CORPORATION	PO BOX 6660	SAN ANTONIO	TX	78209	BEXAR	USA	Child Health and Human Development Extramural Research	000	1	5/27/2008	NEW	$107,000
														Subtotal = $107,000

Grand Total All Awards = $107,000

Top

All Categories

About

Search

Reports

Data Submission

Award Information

NOVEL THERAPY TO TREAT OTITIS MEDIA

Award Number: R43HD058400

ORGANIZATION: NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 06/01/2008

PERIOD OF PERFORMANCE END DATE: 05/31/2009

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer